Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Shares Acquired by Goldman Sachs Group Inc.

Goldman Sachs Group Inc. lifted its stake in shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) by 64.2% during the 4th quarter, HoldingsChannel reports. The firm owned 532,757 shares of the biotechnology company’s stock after purchasing an additional 208,258 shares during the quarter. Goldman Sachs Group Inc.’s holdings in Cerevel Therapeutics were worth $22,589,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Principal Financial Group Inc. boosted its holdings in shares of Cerevel Therapeutics by 1.6% during the 4th quarter. Principal Financial Group Inc. now owns 27,117 shares of the biotechnology company’s stock worth $1,150,000 after purchasing an additional 430 shares during the last quarter. Amalgamated Bank lifted its holdings in Cerevel Therapeutics by 8.8% in the fourth quarter. Amalgamated Bank now owns 10,027 shares of the biotechnology company’s stock valued at $425,000 after acquiring an additional 809 shares during the last quarter. Alps Advisors Inc. lifted its holdings in Cerevel Therapeutics by 0.9% in the third quarter. Alps Advisors Inc. now owns 116,263 shares of the biotechnology company’s stock valued at $2,538,000 after acquiring an additional 984 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Cerevel Therapeutics by 9.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,170 shares of the biotechnology company’s stock valued at $558,000 after acquiring an additional 1,091 shares during the last quarter. Finally, Profund Advisors LLC lifted its holdings in Cerevel Therapeutics by 4.2% in the third quarter. Profund Advisors LLC now owns 33,984 shares of the biotechnology company’s stock valued at $742,000 after acquiring an additional 1,379 shares during the last quarter. 87.73% of the stock is currently owned by institutional investors and hedge funds.

Cerevel Therapeutics Trading Down 4.5 %

CERE opened at $39.56 on Wednesday. Cerevel Therapeutics Holdings, Inc. has a one year low of $19.59 and a one year high of $43.59. The stock has a market capitalization of $7.21 billion, a PE ratio of -14.49 and a beta of 1.42. The business’s 50 day moving average price is $41.63 and its 200 day moving average price is $41.85. The company has a debt-to-equity ratio of 0.60, a quick ratio of 10.22 and a current ratio of 10.22.

Cerevel Therapeutics (NASDAQ:CERE) last released its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.12). As a group, equities research analysts expect that Cerevel Therapeutics Holdings, Inc. will post -2.63 EPS for the current year.

Insider Activity at Cerevel Therapeutics

In other Cerevel Therapeutics news, Director N Anthony Coles sold 50,000 shares of the company’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $42.10, for a total transaction of $2,105,000.00. Following the transaction, the director now directly owns 15,638 shares in the company, valued at $658,359.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.10% of the stock is currently owned by insiders.

Cerevel Therapeutics Profile

Cerevel Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model.